

Menopause (update)

[B1] TSU NMA sensitivity analyses forest plots

NICE guideline number tbc

Supplement 7

November 2023

Draft for consultation

*Supplementary material was developed by the
NICE Technical Support Unit*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).

ISBN:


Menopause (update): supplementary material 7. DRAFT (September 2023)

Contents

Sensitivity analyses forest plots.....	5
---	----------


1 Sensitivity analyses forest plots

2 **Figure 1: Effect of small study effects on mean differences (MD) (back-transformed**
 3 **from SMDs to 0-4 symptom scale) and 95% credible intervals for**
 4 **dyspareunia for each class versus Inactive. MD <0 indicates decreased**
 5 **dyspareunia symptoms versus Inactive. Points indicate the posterior**
 6 **medians and horizontal error bars indicate the 95%CrIs. Base-case NMA**
 7 **results are indicated by a solid blue line and bias-adjusted results by a**
 8 **dashed red line.**




9

1 **Figure 2: Effect of study follow-up on mean differences (MD) (back-transformed from**
 2 **SMDs to 0-4 symptom scale) and 95% credible intervals for dyspareunia for**
 3 **each class versus Inactive. MD <0 indicates decreased dyspareunia**
 4 **symptoms versus Inactive. Points indicate the posterior medians and**
 5 **horizontal error bars indicate the 95%CrIs. Base-case NMA results (including**
 6 **all studies regardless of follow-up) are indicated by a solid blue line and**
 7 **results from an analysis restricted to studies reporting results at 2-12 weeks**
 8 **follow-up by a dashed red line.**



9


1 **Figure 3: Effect of small study effects on mean differences (MD) (back-transformed**
 2 **from SMDs to 0-4 symptom scale) and 95% credible intervals for dryness for**
 3 **each class versus Inactive. MD <0 indicates decreased dryness symptoms**
 4 **versus Inactive. Points indicate the posterior medians and horizontal error**
 5 **bars indicate the 95%CrIs. Base-case NMA results are indicated by a solid**
 6 **blue line and bias-adjusted results by a dashed red line.**



7

8


1 **Figure 4: Effect of study follow-up on mean differences (MD) (back-transformed from**
 2 **SMDs to 0-4 symptom scale) and 95% credible intervals for dryness for each**
 3 **class versus Inactive. MD <0 indicates decreased dryness symptoms versus**
 4 **Inactive. Points indicate the posterior medians and horizontal error bars**
 5 **indicate the 95%CrIs. Base-case NMA results (including all studies**
 6 **regardless of follow-up) are indicated by a solid blue line and results from**
 7 **an analysis restricted to studies reporting results at 2-12 weeks follow-up by**
 8 **a dashed red line.**



9


10

1 **Figure 5: Effect of small study effects on mean differences (MD) (back-transformed**
 2 **from SMDs to 0-4 symptom scale) and 95% credible intervals for discomfort**
 3 **for each class versus Inactive. MD <0 indicates decreased dryness**
 4 **symptoms versus Inactive. Points indicate the posterior medians and**
 5 **horizontal error bars indicate the 95%CrIs. Base-case NMA results are**
 6 **indicated by a solid blue line and bias-adjusted results by a dashed red line**




7

1 **Figure 6: Effect of study follow-up on mean differences (MD) (back-transformed from**
 2 **SMDs to 0-4 symptom scale) and 95% credible intervals for discomfort for each class versus Inactive. MD <0 indicates decreased dryness symptoms**
 3 **versus Inactive. Points indicate the posterior medians and horizontal error**
 4 **bars indicate the 95%CrIs. Base-case NMA results (including all studies**
 5 **regardless of follow-up) are indicated by a solid blue line and results from**
 6 **an analysis restricted to studies reporting results at 2-12 weeks follow-up by**
 7 **a dashed red line.**
 8



9


1 **Figure 7: Effect of small study effects on log-odds ratios (OR) and 95% credible**
 2 **intervals for discontinuation due to adverse events for each class versus**
 3 **Inactive. Log-OR <0 indicates a reduction in discontinuation due to adverse**
 4 **events versus Inactive. Points indicate the posterior medians and horizontal**
 5 **error bars indicate the 95%CrIs. Base-case NMA results are indicated by a**
 6 **solid blue line and bias-adjusted results by a dashed red line**



7

8


1 **Figure 8: Effect of including only studies reporting ITT on mean differences (MD)**
 2 **(back-transformed from SMDs to 0-4 symptom scale) and 95% credible**
 3 **intervals for dyspareunia for each class versus Inactive. MD <0 indicates**
 4 **decreased dyspareunia symptoms versus Inactive. Points indicate the**
 5 **posterior medians and horizontal error bars indicate the 95%CrIs. Base-case**
 6 **NMA results are indicated by a solid blue line and ITT only results by a**
 7 **dashed red line.**



8

9

1 **Figure 9: Effect of including only studies reporting ITT on mean differences (MD)**
 2 **(back-transformed from SMDs to 0-4 symptom scale) and 95% credible**
 3 **intervals for dryness for each class versus Inactive. MD <0 indicates**
 4 **decreased dryness symptoms versus Inactive. Points indicate the posterior**
 5 **medians and horizontal error bars indicate the 95%CrIs. Base-case NMA**
 6 **results are indicated by a solid blue line and ITT only results by a dashed**
 7 **red line.**



8